The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
ustekinumab-aekn
9 marketed package NDCs · 2 active manufacturers
Most dispensed: 45 mg/.5mL · Injection, Solution · #1 tray/carton / 1 syringe, glass in 1 tray / .5 ml in 1 syringe, glass · 90 mg/mL · Injection, Solution · #1 tray/carton / 1 syringe, glass in 1 tray / 1 ml in 1 syringe, glass
Same drug class
Other molecules FDA puts in Interleukin-23 Antagonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Ustekinumab-aekn in shortage right now?
- No. FDA does not currently list Ustekinumab-aekn in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Ustekinumab-aekn?
- 2 companies have marketed Ustekinumab-aekn in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.